Investor News / RNS

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that the newly appointed Board has commenced an extensive review of the business with a clear focus on operational optimisation, commercial execution, and shareholder value creation.   The Board believes the Company possesses a number of underappreciated strengths, including an...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that all resolutions (“Resolutions”) put to shareholders at the general meeting, called by Mr Michael Whitlow, held today (“General Meeting”) were passed.   Click here to read in full...

The following amendment has been made to the 'Results of General Meeting and Board Changes' announcement released on 29 April 2026 at 11:00 under RNS No 4220C.   Addition of “Jim Millen” to the list of the directors who have been removed from the Board with immediate effect in the second paragraph, in accordance with the Resolutions. All other details remain unchanged.   Click here to read in full...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces the launch of a dedicated website aimed at providing key information to shareholders considering their vote in relation to the Company's forthcoming Requisitioned General Meeting to be held at 10.00 a.m. on 29 April 2026 ("Requisitioned General Meeting").   The website is available...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG (“Numab Therapeutics”).   Numab Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology. Under this new contract,...

Further to the Company’s announcement of 2 April 2026, which contained the Resolutions to be voted on at the requestioned general meeting of the Company (the “Requisitioned General Meeting”) to be held at 10.00 a.m. on Wednesday 29 April 2026 at Copthorne Hotel Slough-Windsor, Cippenham Lane, Slough, Berkshire, SL1 2YE, Physiomics provides the following statement from Dr Jim Millen, Chairman of the Company, and republishes...

Further to the Company’s announcement of 16 March 2026, Physiomics announces the publication of a circular (the “Circular”) containing details of a requisitioned general meeting of the Company (the “Requisitioned General Meeting”). The Requisitioned General Meeting will be held at 10.00 a.m. on 29 April 2026 at Copthorne Hotel Slough-Windsor, Cippenham Ln, Slough SL1 2YE.   A summary of the Board’s responses to the Request and Amended...

TR-1: Standard form for notification of major holdings Please click here to read in full...

TR-1: Standard form for notification of major holdings Please click here to read in full...

TR-1: Standard form for notification of major holdings Please click here to read in full...